MATERNUS-Kliniken AG

As of June 30, 2016, MATERNUS-Kliniken AG carries a market capitalization of 29.78M, placing it among publicly traded companies globally. Its enterprise value stands at 111.30M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2016, MATERNUS-Kliniken AG has 20.97M shares outstanding.

As of June 30, 2016, MATERNUS-Kliniken AG trades at a trailing price-to-earnings ratio of 13.39. The price-to-sales ratio is 0.24, and the price-to-book ratio stands at -7.17.

As of June 30, 2016, MATERNUS-Kliniken AG trades at an EV/EBITDA multiple of 8.20 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.90 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 13.44 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 111.30M versus a market cap of 29.78M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2016, MATERNUS-Kliniken AG maintains a current ratio of 0.50, meaning it holds 0.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -2,123.40, indicating conservative leverage, while an interest coverage ratio of 2.44 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2016. Return on invested capital (ROIC) comes in at 8.15 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 1.88, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 8.15, useful for judging operating efficiency across full business cycles. Inventory turnover of 52.84 indicates how many times MATERNUS-Kliniken AG sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2016, MATERNUS-Kliniken AG recorded 504,000.00 in income tax expense. That works out to an effective tax rate of 18.50, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 2.73M, leaving 2.22M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, MATERNUS-Kliniken AG's stock has declined approximately 18.87% over the past 52 weeks. The 50-day moving average sits at 0.87, while the 200-day moving average is 0.95.

Over the twelve months ended June 30, 2016, MATERNUS-Kliniken AG generated 123.88M in revenue and converted that into 2.22M in net income, yielding earnings per share of 0.11. EBITDA reached 13.57M, while operating income came in at 8.28M.

As of June 30, 2016, MATERNUS-Kliniken AG holds 6.66M in cash and equivalents against 88.19M in total debt, resulting in a net debt position of 4.94M. Total book value stands at -4.15M, with working capital of -14.99M providing operational flexibility.

These figures cover the twelve months ended June 30, 2016.

Over the twelve months ended June 30, 2016, MATERNUS-Kliniken AG posted a gross margin of 82.79, reflecting its pricing power and cost economics. The operating margin of 6.68 and net profit margin of 1.79 provide insight into operational efficiency.

MATERNUS-Kliniken AG's most recent stock split took place on March 13, 1997.

As of June 30, 2016, MATERNUS-Kliniken AG has an Altman Z-Score of 0.55, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.